

Freedom of Information Request	FOI 22-308	29 <sup>th</sup> July 2022
--------------------------------	------------	----------------------------

**The following questions with regards to patients treated in your trust are being asked for on behalf of Novartis.**

- 1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?**

**February to May 2022**

**Outpatient Attendances:**

Primary Diagnosis*	Feb	Mar	Apr	May
<b>Psoriasis</b>	231	221	233	241
<b>Rheumatoid Arthritis</b>	210	208	235	352

\* Primary diagnosis is the main condition treated or investigated during the episode of care.

Please note coding of outpatient information is undertaken by relevant service but is not mandatory, therefore the data provided may not be complete.

**Inpatient/Daycase Admissions:**

Primary Diagnosis*	Feb	Mar	Apr	May
<b>Hidradenitis Suppurativa</b>			<5	
<b>Psoriatic Arthritis</b>			<5	<5
<b>Psoriasis</b>	<5			
<b>Rheumatoid Arthritis</b>	<5	<5	<5	<5

Where relevant the Health Board has applied Section 40 of the Freedom of Information Act 2000. The Health Board will not provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**2) Of these five, how many of each received the following products:**

- **Adalimumab (Humira)**
- **Adalimumab Biosimilar**
- **Etanercept (Enbrel)**
- **Etanercept Biosimilar**
- **Infliximab (Remicade)**
- **Infliximab biosimilar**
- **Golimumab (Simponi)**
- **Tofacitinib (Xeljanz)**
- **Ustekinumab (Stelara)**
- **Vedolizumab (Entyvio)**
- **Filgotinib (Jyseleca)**
- **Abatacept (Orencia)**
- **Baricitinib (Olumiant)**
- **Certolizumab Pegol (Cimzia)**
- **Rituximab (MabThera)**
- **Rituximab Biosimilar**
- **Tocilizumab (RoActemra)**
- **Sarilumab (Kevzara)**
- **Apremilast (Otezla)**
- **Secukinumab (Cosentyx)**
- **Isekizumab (Taltz)**
- **Guselkumab (Tremfya)**
- **Brodalumab (Kyntheum)**
- **Risankizumab (Skyrizi)**
- **Tildrakizumab (Ilumetri)**
- **Upadacitinib (Rinvoq)**
- **Bimekizumab (Bimzelx)**

Please find below the quantities dispensed from the Health Board pharmacies for the period February 2022 to May 2022. The Health Board is only able to supply information by quantity and not by the number of patients treated.

Please note the products dispensed below are attributed to Rheumatology and Gastroenterology only, however, the Health Board is unable to confirm if these products were used to treat the diseases in Q1.

<b>Type</b>	<b>Quantity</b>
ABATACEPT (ORENCIA CLICKJECT) 125 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack (Rheumatology)	24
ABATACEPT (ORENCIA) 125 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack (Rheumatology)	44
ABATACEPT 250 mg Intravenous Infusion 1 Vial Pack (Rheumatology)	2
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Gastroenterology)	1033
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	4
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack (Gastroenterology)	15
GADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Gastroenterology)	21
GADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	141

Type	Quantity
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack (Rheumatology)	46
ADALIMUMAB (IMRALDI) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	264
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	144
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	215
ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack (Rheumatology)	347
ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack (Rheumatology)	35
ETANERCEPT (ENBREL) 25 mg in 0.5mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack (Rheumatology)	16
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack (Rheumatology)	36
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack (Rheumatology)	12
GOLIMUMAB (SIMPONI) 100 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack (Rheumatology)	8
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Pen 1 Pre-Filled Pen Pack (Rheumatology)	62
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack (Rheumatology)	4
INFLIXIMAB (FLIXABI) 100 mg Intravenous Infusion 1 Vial Pack (Rheumatology)	1711
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack (Gastroenterology)	20
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack (Rheumatology)	15
INFLIXIMAB (REMICADE) 100 mg Intravenous Infusion 1 Vial Pack (Rheumatology)	10
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack (Rheumatology)	80
SARILUMAB (KEVZARA) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	32
SARILUMAB (KEVZARA) 200 mg in 1.14mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack (Rheumatology)	2
SECUKINUMAB 150 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack (Rheumatology)	87
SECUKINUMAB 150 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack (Rheumatology)	3
SECUKINUMAB 300 mg in 2mL Pre-Filled Pen 1 Pre-Filled Pen Pack (Rheumatology)	5
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Pen 4 Pre-Filled Pen Pack (Rheumatology)	77
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack (Rheumatology)	105
TOCILIZUMAB 200 mg in 10mL Intravenous Infusion 1 Vial Pack (Rheumatology)	9
TOCILIZUMAB 400 mg in 20mL Intravenous Infusion 1 Vial Pack (Rheumatology)	23
TOCILIZUMAB 80 mg in 4mL Intravenous Infusion 1 Vial Pack (Rheumatology)	30
TOFACITINIB 5 mg Tablets 56 Tablet Pack (Gastroenterology)	9
TOFACITINIB 5 mg Tablets 56 Tablet Pack (Rheumatology)	21
USTEKINUMAB 130 mg in 26mL Intravenous Infusion 1 Vial Pack (Gastroenterology)	16

Type	Quantity
USTEKINUMAB 45 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack (Rheumatology)	13
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack (Gastroenterology)	133
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack (Rheumatology)	6
VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Pen 1 Pre-Filled Pen Pack (Gastroenterology)	831
VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	12
VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial Pack (Gastroenterology)	332

**3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).**

The Health Board does not record this information centrally, in order to determine a response for the rest of the information requested the Health Board would have to review every patient record. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

**4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?**

- **AxSPA**
- **PsA**
- **PsO**

Please refer to Q3.